Advertisement
Advertisement
  • GlobeNewswire

    Press Release: Sanofi provides update on amcenestrant clinical development program

    Sanofi provides update on amcenestrant clinical development program PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive

  • GlobeNewswire

    BGHL (EUR): NAV(s)

    BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 16 Aug 2022. Estimated NAV Euro Shares Sterling Shares Estimated NAV € 27.6878 £ 24.1816 Estimated MTD return 1.04 % 1.13 % Estimated YTD return -5.18 % -4.44 % Estimated ITD return 176.88 % 141.82 % NAV and returns are calculated net of management and performance fees Market information Euro Shares Amsterdam

  • GlobeNewswire

    Nykredit Bank A/S H1 Interim Report 2022

    To Nasdaq Copenhagen A/Sand the press17 August 2022 Nykredit today announces its H1 Interim Reports 2022 of: Nykredit A/S, CVR no 12 71 92 48Nykredit Realkredit A/S, CVR no 12 71 92 80Nykredit Bank A/S, CVR no 10 51 96 08Totalkredit A/S, CVR no 21 83 22 78 Michael Rasmussen, Group Chief Executive, comments on Nykredit's H1 Interim Report 2022: Our half-year results presented today are highly satisfactory with profit before tax and business profit of DKK 5,015 million and DKK 4,344 million, respe